Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Senate panel moves meth bill

This article was originally published in The Tan Sheet

Executive Summary

The Senate Judiciary Committee approves legislation to prevent mass purchases of methamphetamine precursors by facilitating use of electronic logbooks in pharmacies through state and local government grants, according to bill co-sponsor Sen. Chuck Grassley, R-Iowa. The Methamphetamine Production Prevention Act of 2007, S. 1276, aims to stop "smurfing" - buying nonprescription, pseudoephedrine-containing cold or allergy remedies in small quantities at multiple pharmacies - by making "electronic logbook systems far more cost-effective without hurting law enforcement efforts," Grassley says in a Sept. 11 release. The bill was introduced in May 2007 by Sen. Dick Durbin, D-Ill., to add the electronic logbook provision omitted by 2006's Combat Meth Act (1"The Tan Sheet" May 7, 2007, p. 3). A companion bill, H.R. 2747, has not moved since being referred to a House Judiciary subcommittee in July 2007 (2"The Tan Sheet" June 25, 2007, In Brief). Several states, including Arkansas and Iowa, have introduced their own e-tracking systems (3"The Tan Sheet" June 9, 2008, In Brief)

You may also be interested in...

Durbin Introduces Pseudoephedrine Electronic Log Bill To Fight Smurfing

A bill introduced in Congress May 3 funds the creation of electronic databases to record pseudoephedrine purchases, in an effort to improve enforcement of existing methamphetamine precursor control laws

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts